Abstract Number: 0947 • ACR Convergence 2021
Cytokine Competent Gut-joint Migratory T Cells Contribute to Inflammation in the Joint
Background/Purpose: Although studies have identified the presence of gut-associated cells in the enthesis of joints affected by spondyloarthritis, a direct link through cellular transit between…Abstract Number: 1802 • ACR Convergence 2021
Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials
Background/Purpose: Axial, peripheral, and other disease manifestations often overlap between psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Upadacitinib (UPA) is an oral Janus kinase inhibitor…Abstract Number: L11 • ACR Convergence 2020
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for the treatment of adult patients (pts) with AS.Methods: This Phase 3, randomized, double-blind…Abstract Number: 0038 • ACR Convergence 2020
Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study
Background/Purpose: Axial Spondyloarthritis (AS) is amongst the most common forms of inflammatory arthritis. Widely used in the treatment of axSpA, adalimumab is an engineered antibody…Abstract Number: 0448 • ACR Convergence 2020
Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A mutlicenter study with 806 patients.
Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) due to a process of accelerated atherosclerosis. The disease-related factors involved in this…Abstract Number: 1309 • ACR Convergence 2020
Prevalence of Undiagnosed Axial Spondyloarthritis Among Patients with Inflammatory Bowel Disease: A Secondary Care Cross-Sectional Study
Background/Purpose: Axial spondyloarthritis (axSpA) is closely related to inflammatory bowel disease (IBD), however contemporary data on the burden of hidden disease in the IBD population…Abstract Number: 1359 • ACR Convergence 2020
Targeted Serum Proteomic Analysis Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue Repair Modulation
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to…Abstract Number: 1867 • ACR Convergence 2020
Two-Year Diagnostic Consistency in Patients with Chronic Back Pain Suspected of Axial Spondyloarthritis in Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Background/Purpose: A diagnosis of (early) axial spondyloarthritis (axSpA) is based on pattern recognition, which can be challenging and may change over time. The aim of…Abstract Number: 1892 • ACR Convergence 2020
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
Background/Purpose: Ankylosing Spondylitis Disease Activity Score (ASDAS) is adopted to evaluate the degree of disease activity and the inflammatory response in AS patients. ASDAS score…Abstract Number: 0080 • ACR Convergence 2020
Understanding Ankylosing Spondylitis –
Background/Purpose: Rheumatology is underrepresented in the medical training of students in Germany. [1] Tools and methods are needed to inspire young students for specialist training…Abstract Number: 0455 • ACR Convergence 2020
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…Abstract Number: 1310 • ACR Convergence 2020
Gut Microbiome Changes Are Different Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Disease Activity in Both Diseases
Background/Purpose: Multiple studies have confirmed that the gut and stool microbiome in ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are distinct from healthy controls,…Abstract Number: 1362 • ACR Convergence 2020
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) have proven to be safe and effective in the treatment of axial spondyloarthritis (axSpA). However, they carry some disadvantages,…Abstract Number: 1868 • ACR Convergence 2020
Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Background/Purpose: The aim of this study was to compare quality of life (QoL) between chronic back pain (CBP) patients with and without a diagnosis of…Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 57
- Next Page »